MiRNA in Situ Hybridization in Circulating Tumor Cells--MishCTC

Overview

Journal Sci Rep

Specialty Science

Date 2015 Mar 18

PMID 25777797

Citations 21

Authors

Francisco G Ortega

Jose A Lorente

Jose L Garcia Puche

Maria P Ruiz

Rosario M Sanchez-Martin

Diego de Miguel-Perez

Juan J Diaz-Mochon

Maria J Serrano

Affiliations

Soon will be listed here.

Abstract

Circulating tumor cells (CTCs) must be phenotypically and genetically characterized before they can be utilized in clinical applications. Here, we present the first protocol for the detection of miRNAs in CTCs using in situ hybridization (ISH) combined with immunomagnetic selection based on cytokeratin (CK) expression and immunocytochemistry. Locked-Nucleic Acid (LNA) probes associated with an enzyme-labeled fluorescence (ELF) signal amplification approach were used to detect miRNA-21 in CTCs. This protocol was optimized using both epithelial tumor (MDA-MB468) and epithelial non-tumor (MCF-10A) cell lines, and miRNA-21 was selected as the target miRNA because of its known role as an onco-miRNA. Hematopoietic cells do not express miRNA-21; thus, miRNA-21 is an ideal marker for detecting CTCs. Peripheral blood samples were taken from 25 cancer patients and these samples were analyzed using our developed protocol. Of the 25 samples, 11 contained CTCs. For all 11 CTC-positive samples, the isolated CTCs expressed both CK and miRNA-21. Finally, the protocol was applied to monitor miRNA-21 expression in epithelial to mesenchymal transition (EMT)-induced MCF-7 cells, an epithelial tumor cell line. CK expression was lost in these cells, whereas miRNA-21 was still expressed, suggesting that miRNA-21 might be a good marker for detecting CTCs with an EMT phenotype.

Citing Articles

Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?.

Radhakrishnan V, Kaifi J, Suvilesh K Cancers (Basel). 2024; 16(4).

PMID: 38398206 PMC: 10887304. DOI: 10.3390/cancers16040816.

Meta analysis of the diagnostic value of circulating miRNA in benign and malignant pulmonary nodules.

Hong Z, Cui B, Bai X, Li H, Cheng T, Sheng Y World J Surg Oncol. 2023; 21(1):284.

PMID: 37689670 PMC: 10492278. DOI: 10.1186/s12957-023-03133-3.

Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?.

Visal T, den Hollander P, Cristofanilli M, Mani S Br J Cancer. 2022; 127(2):173-184.

PMID: 35273384 PMC: 9296521. DOI: 10.1038/s41416-022-01768-9.

Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies.

Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Farinas S, Exposito F, Serrano D Cancers (Basel). 2021; 13(12).

PMID: 34208598 PMC: 8233712. DOI: 10.3390/cancers13123016.

Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.

Balazs K, Antal L, Safrany G, Lumniczky K J Pers Med. 2021; 11(4).

PMID: 33924671 PMC: 8070149. DOI: 10.3390/jpm11040296.

References

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Serrano M, Ortega F, Alvarez-Cubero M, Nadal R, Sanchez-Rovira P, Salido M . EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. Oncotarget. 2014; 5(17):7486-97. PMC: 4202138. DOI: 10.18632/oncotarget.2217. View

Mehlen P, Puisieux A . Metastasis: a question of life or death. Nat Rev Cancer. 2006; 6(6):449-58. DOI: 10.1038/nrc1886. View

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

Tricoli J, Jacobson J . MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. Cancer Res. 2007; 67(10):4553-5. DOI: 10.1158/0008-5472.CAN-07-0563. View

Pena J, Sohn-Lee C, Rouhanifard S, Ludwig J, Hafner M, Mihailovic A . miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods. 2009; 6(2):139-41. PMC: 2838186. DOI: 10.1038/nmeth.1294. View

Lu J, Tsourkas A . Imaging individual microRNAs in single mammalian cells in situ. Nucleic Acids Res. 2009; 37(14):e100. PMC: 2724290. DOI: 10.1093/nar/gkp482. View

Croce C . Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10(10):704-14. PMC: 3467096. DOI: 10.1038/nrg2634. View

Medina P, Nolde M, Slack F . OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467(7311):86-90. DOI: 10.1038/nature09284. View

10.

Sieuwerts A, Mostert B, Vries J, Peeters D, de Jongh F, Stouthard J . mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 2011; 17(11):3600-18. DOI: 10.1158/1078-0432.CCR-11-0255. View

11.

Bornachea O, Santos M, Martinez-Cruz A, Garcia-Escudero R, Duenas M, Costa C . EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep. 2012; 2:434. PMC: 3364492. DOI: 10.1038/srep00434. View

12.

Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche J . Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012; 14(3):R71. PMC: 3446333. DOI: 10.1186/bcr3180. View

13.

Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M . Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res. 2012; 18(21):5972-82. DOI: 10.1158/1078-0432.CCR-12-1407. View

14.

Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339(6119):580-4. PMC: 3760262. DOI: 10.1126/science.1228522. View

15.

Zhao S, Yang H, Zhang M, Zhang D, Liu Y, Liu Y . Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Cell Biochem Biophys. 2012; 65(2):263-73. DOI: 10.1007/s12013-012-9426-2. View

16.

Nadal R, Lorente J, Rosell R, Serrano M . Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies. Expert Rev Mol Diagn. 2013; 13(3):295-307. DOI: 10.1586/erm.13.7. View

17.

Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P . A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012; 41(4):1241-50. PMC: 3583719. DOI: 10.3892/ijo.2012.1557. View

18.

Li Z, Liang Y, Lau P, Shen W, Wang D, Cheung W . Dynamic localisation of mature microRNAs in Human nucleoli is influenced by exogenous genetic materials. PLoS One. 2013; 8(8):e70869. PMC: 3735495. DOI: 10.1371/journal.pone.0070869. View

19.

Schulze K, Gasch C, Staufer K, Nashan B, Lohse A, Pantel K . Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013; 133(9):2165-71. DOI: 10.1002/ijc.28230. View

20.

Yamada M, Kubo H, Ota C, Takahashi T, Tando Y, Suzuki T . The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells. Respir Res. 2013; 14:95. PMC: 3849377. DOI: 10.1186/1465-9921-14-95. View